Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
EP: 1.Frontline Maintenance Therapy in Ovarian Cancer
EP: 2.Ovarian Cancer: Deciding Between Treatment Options
EP: 3.Unmet Needs in the Maintenance Setting in Ovarian Cancer
EP: 4.Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer
EP: 5.Efficacy of Subsequent Therapies in Advanced Ovarian Cancer
Now Viewing
EP: 6.Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
EP: 7.Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer
EP: 8.MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer
EP: 9.Recently Presented Data on Endometrial Cancer
EP: 10.NRG-GY018 and RUBY Trials in Endometrial Cancer
EP: 11.The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer
EP: 12.KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
EP: 13.Ongoing Trials in Endometrial Cancer
EP: 14.Future Outlook for Treatment of Endometrial Cancer
Related Videos
Related Content
